No Data
No Data
ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets
China's medical products administrator granted HeiLongJiang ZBD Pharmaceutical (SHA:603567) a drug registration certificate for its esomeprazole magnesium enteric-coated tablets for gastric acid secre
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Heilongjiang ZBD Pharmaceutical's (SHSE:603567) stock is up by a considerable 15% over the past three months. However, we decided to pay attention to the company's fundamentals which don't appear to
China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable
China's medical products administrator granted HeiLongJiang ZBD Pharmaceutical (SHA:603567) a drug registration certificate for its levetiracetam concentrated solution for injection, according to a Tu
Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Looks Inexpensive But Perhaps Not Attractive Enough
With a price-to-earnings (or "P/E") ratio of 20x Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) may be sending bullish signals at the moment, given that almost half of all companies in China
Earnings Growth of 108% Over 1 Year Hasn't Been Enough to Translate Into Positive Returns for Heilongjiang ZBD Pharmaceutical (SHSE:603567) Shareholders
Investors can approximate the average market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Unfortunately the Heilongj
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets
Heilongjiang ZBD Pharmaceutical (SHA:603567) obtained a drug registration certificate for tofacitinib citrate tablets from China's National Medical Products Administration. The drug is used to treat a
No Data